Navigation Links
ApoCell's Cancer Predictive Index Helps Oncologists Select the Most,Effective Targeted Drug Therapy

By knowing a patient's PDx Index(TM) score ahead of time, the physician can prescribe the right drug treatment that has the highest probability of success for that individual."

About ApoCell, Inc.

ApoCell was founded in 2004 to commercialize biomarker technologies that were developed at the University of Texas M.D. Anderson Cancer Center. This proprietary method monitors the effectiveness of cancer drugs by measuring biomarker expression patterns in patient specimens. ApoCell provides analytical biomarker services to pharmaceutical and biotechnology companies, and clinical researchers in academia and government to assist them in developing new therapeutic agents. ApoCell's technology has been tested in 38 clinical studies with over 11,000 specimens on 28 investigational drugs including six FDA approved cancer drugs. ApoCell's molecular-based diagnostics have application in oncology and other diseases. For more information, please visit www.apocell.com.

Contact

ApoCell, Inc., Houston
Darren Davis, 713-440-6070


'"/>




Page: 1 2

Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Protox Announces Positive Clinical Data from Prostate Cancer Study
6. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
7. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
8. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
11. Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression

Post Your Comments:
(Date:11/6/2009)... 6 Facet Solutions, Inc. announced...rchus Orthopedics. The acquisition creates an undi...ntellectual property and clinical experience in po...tients suffering from lumbar spinal stenosis," sta...rdo. "This consolidation further strengthens Face...
(Date:11/6/2009)... Virtual Health Technolo...day that the previously confirmed Letter of Intent...anagement Technologies, Inc (WNDM) is subject to f...holders of VHGI. ,, Shareholder Assurances ...d, royalty stream and cash realized from the trans...
(Date:11/6/2009)...ewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nas...he development of small-molecule therapeutics for ...ciency virus (HIV), today reported recent accompli...r and nine months ended September 30, 2009. ,,...1104/ARDEALOGO ) ,, "Since our last quarterly u...
Breaking Medicine Technology:Facet Solutions Acquires Archus Orthopedics 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 3OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 4Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 6Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 7Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 8Misonix Receives First Award for Forensic Equipment in China 52275 1Misonix Receives First Award for Forensic Equipment in China 52275 2Webmedx Appoints New Senior Vice President of Client Development Chris Cashwell 52271 1Webmedx Appoints New Senior Vice President of Client Development Chris Cashwell 52271 2Major NIMH research project to test approaches to altering the course of schizophrenia 52267 1Major NIMH research project to test approaches to altering the course of schizophrenia 52267 2Major NIMH research project to test approaches to altering the course of schizophrenia 52267 3
...DENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - Cala...company and a,majority-owned subsidiary of Arrowhe...he publication in the Proceedings of the,National ... of the,NAS, of the first non-human primate study ...ad siRNA therapeutic candidate that is a,nanoparti...
...ies Show Increased Enzyme Levels in Two Most Commo...swire/ -- Amicus,Therapeutics, a biopharmaceutical...tered pharmacological chaperones for the,treatment...oday,that it will present the results of preclinic...T2101) for Gaucher disease at,the of Medical Genet...
Other Medicine Technology:Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 2Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 3Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 4Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 5Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3
(Date:11/7/2009)...wswire-USNewswire/ -- The American Medical Associa...of Health at the Family Violence Prevention Fund, ...at its semi-annual policy-making meeting. The Cit...or the AMA House of Delegates bestows on a non-phy...gi-bin/prnh/20081209/AMALOGO ) ,, "Ms. James ...
(Date:11/7/2009)...wswire-USNewswire/ -- Members of the AMA are tryin...esolution rescinding the AMA,s support of HR 3962....e responsible to their PATIENTS, not the leadershi...licy for the Association of American Physicians an... other medical groups. ,, "If the AMA leadersh...
(Date:11/7/2009)...RNewswire-USNewswire/ -- The U.S. bishops November...o vote for the Stupak-Ellsworth Amendment to the h...ts-Kaptur-Dahlkemper-Lipinski-Smith Amendment will...ding and conscience protections in the Affordable ...d. ,, The letter was signed by Cardinal Justin ...
(Date:11/7/2009)...ic Relations Society of America (PRSA) will bestow...ofgren, senior vice president of Brand Strategy, C...t at a ceremony at PRSA,s 2009 International Confe...PRSA College of Fellows is one of the profession,s...APR, SAGE, Fellow PRSA, and 2009 chair of the Coll...
(Date:11/7/2009)...tober 23-25th marked the 12th annual tournament br...he battle against pediatric cancer. Stephen Updeg...forts for many years. , S...e weekend of October 23-25 marked the 12th annual...ies fighting the battle against pediatric cancer&n...
Breaking Medicine News(10 mins):Health News:AMA Honors Family Violence Prevention Expert 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 3Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 2Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 3
...dice and hope they come up seven: on Saturday thou...rt city to gamble that the lucky number holds the...tal of the world, couples are lining up to get mar...weddings for decades and at large glitzy resorts w...
...lantable cardioverter defibrillators in Canada is ...hat in the United States. Dr. David Birnie and col...ute report that, between 1995 and 2003, the use of...rom 9.7% to 42.0%. Implantable cardioverter ...
... huggers but now by Madonna, Sting and other stars... adopted as a celebrity campaign issue in Saturda...istory, climate change has faced indifference or i...eenmongering scare. Thirty years ago, only...
...search teams at Glasgow University and Baylor Coll...regulators of SCC development, providing insights...isease. Squamous cell carcinoma (SCC) is a fo... in the p53 tumor suppressor gene have been implic...
...nal Cricket Council (ICC) and the Pakistan Cricket...doping rules , the World-Anti Doping Agency (WADA)...verely hampered if this is not take care of. ...ensure that their anti-doping rules are able to av...
...announced that with the initiation of a new study ...geles, it will accelerate the recruitment of pati...dy of EPC2407, a novel small molecule vascular dis...ve been completed according to schedule at Scottsd...
Other Medicine News:Health News:Will Seven Be the Lucky Number for Las Vegas Newlyweds? 2Health News:Live Earth: How Global Warming Became Cool 2Health News:Live Earth: How Global Warming Became Cool 3Health News:Skin Cancer can Be Triggered by P53 Mutation 2Health News:Anti-doping Rules Must Avoid Unsatisfactory Decisions: WADA 2Health News:EpiCept Accelerates Development of Phase I Clinical Study for Cancer 2
MSV-10 Adjustable Velcro
Wide Belt Wrap Around
Wide Belt
Vari-Stim® Hand-Held Nerve Locator/Stimulator
Medicine Products: